Idec Eyes Success
Executive Summary
Troubles that made Idec drop its lead drug convinced it to take on manufacturing. From a stock price in June 1994 of $2.44 to a stock price of $24 in September 1996, whatever becomes of the products now coming through Idec's pipeline, the strategy that got it out of some bad times is worth a closer look.
You may also be interested in...
Biotechs on the Brink Choose Last-Minute Deals, Not Liquidation
Many biotechs, facing crisis situations in the fall of 2002, opted for deals that kept them alive but hardly offered much hope for upside. But in the coming months, boards may need to be far more realistic about their long-term prospects and consider a full range of options, including liquidation, when assessing a company's future.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.